CASC2 and glioma: Long non-coding RNAs (lncRNAs) are a group of non-protein-coding RNAs.5 Recently, aberrant lncRNAs expression is observed in many kinds of cancers, and lncRNAs have caught increasing attention for their roles in cancer progression.6 Cancer susceptibility candidate 2 (CASC2) is a member of lncRNAs and is known as a novel tumor suppressor.7 CASC2 has been reported to modulate resistance to temozolomide (TMZ)-based chemotherapy in glioma tumorigenesis.8,9 However, the effect of CASC2 on cisplatin cytotoxicity in non-small cell lung cancer (NSCLC) is unknown.